Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
Recruiting
AstraZeneca
Phase 1
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women
with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)
A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer
Active, not recruiting
AstraZeneca
Phase 2
This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to
compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in
women with advanced breast cancer.
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer
Recruiting
AstraZeneca
Phase 1
This is a Phase 1, open-label study designed to evaluate the safety, tolerability,
pharmacokinetics, and anti-tumor activity of AZD9833 in Japanese women with
endocrineresistant ER+ HER2- breast cancer that is not amenable to treatment with curative
intent. This study consists of 2 cohorts, Cohort1 and Cohort2. In cohort 1 (for tolerability
evaluation), a minimum of 3, or up to 6, evaluable Japanese patients with ER+ HER2- breast
cancer will be enrolled. In cohort 2 (for exploratory research), at least 6 to maximum 12
evaluable Japanese patients with ER+ HER2- breast cancer will be enrolled.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
